Magnolol
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 319613

CAS#: 528-43-8

Description: Magnolol is known to act on the GABAA receptors in rat cells in vitro as well as having antifungal properties. Magnolol has a number of osteoblast-stimulating and osteoclast-inhibiting activities in cell culture and has been suggested as a candidate for screening for anti-osteoporosis activity. It has anti-periodontal disease activity in a rat model. Magnolol is a bioactive compound found in the bark of the Houpu magnolia (Magnolia officinalis) or in M. grandiflora. The compound exists at the level of a few percent in the bark of species of magnolia, the extracts of which have been used in traditional Chinese and Japanese medicine. In addition to magnolol, related lignans occur in the extracts including honokiol, which is an isomer of magnolol.


Chemical Structure

img
Magnolol
CAS# 528-43-8

Theoretical Analysis

MedKoo Cat#: 319613
Name: Magnolol
CAS#: 528-43-8
Chemical Formula: C18H18O2
Exact Mass: 266.13
Molecular Weight: 266.340
Elemental Analysis: C, 81.17; H, 6.81; O, 12.01

Price and Availability

Size Price Availability Quantity
200mg USD 110 Ready to ship
1g USD 250 2 weeks
5g USD 550 2 weeks
10g USD 850 2 Weeks
Bulk inquiry

Synonym: Magnolol; Dehydrodichavicol; 5,5'-Diallyl-2,2'-dihydroxybiphenyl; 5,5'-Diallyl-2,2'-biphenyldiol.

IUPAC/Chemical Name: 5,5'-diallyl-[1,1'-biphenyl]-2,2'-diol

InChi Key: VVOAZFWZEDHOOU-UHFFFAOYSA-N

InChi Code: InChI=1S/C18H18O2/c1-3-5-13-7-9-17(19)15(11-13)16-12-14(6-4-2)8-10-18(16)20/h3-4,7-12,19-20H,1-2,5-6H2

SMILES Code: OC1=CC=C(CC=C)C=C1C2=CC(CC=C)=CC=C2O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2917.39.7000

More Info:

Product Data:
Safety Data Sheet (SDS):
Biological target: Magnolol is a dual agonist of both RXRα and PPARγ, with EC50 values of 10.4 µM and 17.7 µM, respectively.
In vitro activity: First, the stimulation of HGFs (human gingival fibroblasts) with AGE (Advanced Glycation End Product) (500 μg/mL) markedly induced the production of ROS, while administration of various concentrations (0–10 μM) of Magnolol dose-dependently downregulated the generation of ROS (Fig. 1). This finding indicated that Magnolol possessed the anti-oxidant capacity. To explore how Magnolol regulated the AGE-induced oxidative stress, the expression of Nrf2 and HO-1 was assessed in order to ascertain Magnolol was able to modulate this antioxidant pathway. As expected, AGEs suppressed the expression of both Nrf2 and HO-1 (Fig. 4), which was consistent with the abovementioned observation of a higher ROS production in the AGE-treated HGFs. Magnolol increased the expression Nrf2/HO-1 axis in a dose-dependent fashion (Fig. 4), suggesting Magnolol may mitigate the generation of ROS through activation of Nrf2/HO-1 signaling. Reference: J Formos Med Assoc. 2021 Feb 10:S0929-6646(21)00027-9. https://pubmed.ncbi.nlm.nih.gov/33581965/
In vivo activity: The potential underlying mechanisms of magnolol treatment in psoriasis-like skin were examined using the inflammatory cytokine panel. The cytokine array results revealed that the expression of all the cytokines were significantly increased in the mouse control group (IMQ (imiquimod)-induced only) compared with the normal group (untreated skin specimens, P<0.05). High-dose administration of magnolol led to the inhibition of IL-23, IL-1β, IL-6, TNF-α and INF-γ protein expression (all P<0.05), although not of IL-17A (P>0.05), compared with the control group. Low-dose administration of magnolol led to the inhibition of IL-23, IL-1β, IL-6 and INF-γ protein expression (all P<0.05) although not of IL-17A and TNF-α (both P>0.05), compared with the control group. Both high and low administration of magnolol led to the inhibition of IL-1β compared with the EtOH group (both P<0.05). Reference: Exp Ther Med. 2021 May; 21(5): 448. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7967813/

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
DMSO 56.3 211.51
DMF 20.0 75.09
Ethanol 36.5 137.15
Ethanol:PBS (pH 7.2) (1:5) 0.2 0.60

Preparing Stock Solutions

The following data is based on the product molecular weight 266.34 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol: 1. Liu CM, Chen SH, Liao YW, Yu CH, Yu CC, Hsieh PL. Magnolol ameliorates the accumulation of reactive oxidative stress and inflammation in diabetic periodontitis. J Formos Med Assoc. 2021 Feb 10:S0929-6646(21)00027-9. doi: 10.1016/j.jfma.2021.01.010. Epub ahead of print. PMID: 33581965. 2. Peng CY, Yu CC, Huang CC, Liao YW, Hsieh PL, Chu PM, Yu CH, Lin SS. Magnolol inhibits cancer stemness and IL-6/Stat3 signaling in oral carcinomas. J Formos Med Assoc. 2021 Feb 4:S0929-6646(21)00026-7. doi: 10.1016/j.jfma.2021.01.009. Epub ahead of print. PMID: 33551310. 3. Guo JW, Cheng YP, Liu CY, Thong HY, Lo Y, Wu CY, Jee SH. Magnolol may contribute to barrier function improvement on imiquimod-induced psoriasis-like dermatitis animal model via the downregulation of interleukin-23. Exp Ther Med. 2021 May;21(5):448. doi: 10.3892/etm.2021.9876. Epub 2021 Mar 1. PMID: 33747183; PMCID: PMC7967813. 4. Chen S, Shen J, Zhao J, Wang J, Shan T, Li J, Xu M, Chen X, Liu Y, Cao G. Magnolol Suppresses Pancreatic Cancer Development In Vivo and In Vitro via Negatively Regulating TGF-β/Smad Signaling. Front Oncol. 2020 Dec 2;10:597672. doi: 10.3389/fonc.2020.597672. PMID: 33344246; PMCID: PMC7738609.
In vitro protocol: 1. Liu CM, Chen SH, Liao YW, Yu CH, Yu CC, Hsieh PL. Magnolol ameliorates the accumulation of reactive oxidative stress and inflammation in diabetic periodontitis. J Formos Med Assoc. 2021 Feb 10:S0929-6646(21)00027-9. doi: 10.1016/j.jfma.2021.01.010. Epub ahead of print. PMID: 33581965. 2. Peng CY, Yu CC, Huang CC, Liao YW, Hsieh PL, Chu PM, Yu CH, Lin SS. Magnolol inhibits cancer stemness and IL-6/Stat3 signaling in oral carcinomas. J Formos Med Assoc. 2021 Feb 4:S0929-6646(21)00026-7. doi: 10.1016/j.jfma.2021.01.009. Epub ahead of print. PMID: 33551310.
In vivo protocol: 1. Guo JW, Cheng YP, Liu CY, Thong HY, Lo Y, Wu CY, Jee SH. Magnolol may contribute to barrier function improvement on imiquimod-induced psoriasis-like dermatitis animal model via the downregulation of interleukin-23. Exp Ther Med. 2021 May;21(5):448. doi: 10.3892/etm.2021.9876. Epub 2021 Mar 1. PMID: 33747183; PMCID: PMC7967813. 2. Chen S, Shen J, Zhao J, Wang J, Shan T, Li J, Xu M, Chen X, Liu Y, Cao G. Magnolol Suppresses Pancreatic Cancer Development In Vivo and In Vitro via Negatively Regulating TGF-β/Smad Signaling. Front Oncol. 2020 Dec 2;10:597672. doi: 10.3389/fonc.2020.597672. PMID: 33344246; PMCID: PMC7738609.

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Kim DJ, Kim YS. Magnolol protects against trimethyltin-induced neuronal damage and glial activation in vitro and in vivo. Neurotoxicology. 2016 Jan 3. pii: S0161-813X(16)30001-8. doi: 10.1016/j.neuro.2016.01.001. [Epub ahead of print] PubMed PMID: 26756313.

2: Pei YL, Wu ZS, Shi XY, Pan XN, Peng YF, Qiao YJ. [NIR Assignment of Magnolol by 2D-COS Technology and Model Application Huoxiangzhengqi Oral Liduid]. Guang Pu Xue Yu Guang Pu Fen Xi. 2015 Aug;35(8):2119-23. Chinese. PubMed PMID: 26672278.

3: Bunel V, Antoine MH, Stévigny C, Nortier J, Duez P. New in vitro insights on a cell death pathway induced by magnolol and honokiol in aristolochic acid tubulotoxicity. Food Chem Toxicol. 2016 Jan;87:77-87. doi: 10.1016/j.fct.2015.11.020. Epub 2015 Nov 27. PubMed PMID: 26631295.

4: Zhang X, Huang H, Chang H, Jin X. Magnolol reduces bleomycin-induced rodent lung fibrosis. Int J Clin Exp Med. 2015 Sep 15;8(9):15450-7. eCollection 2015. PubMed PMID: 26629034; PubMed Central PMCID: PMC4658923.

5: Zuo GY, Zhang XJ, Han J, Li YQ, Wang GC. In vitro synergism of magnolol and honokiol in combination with antibacterial agents against clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA). BMC Complement Altern Med. 2015 Dec 1;15(1):425. doi: 10.1186/s12906-015-0938-3. PubMed PMID: 26627468; PubMed Central PMCID: PMC4666064.

6: Chen MC, Chen YL, Lee CF, Hung CH, Chou TC. Supplementation of Magnolol Attenuates Skeletal Muscle Atrophy in Bladder Cancer-Bearing Mice Undergoing Chemotherapy via Suppression of FoxO3 Activation and Induction of IGF-1. PLoS One. 2015 Nov 24;10(11):e0143594. doi: 10.1371/journal.pone.0143594. eCollection 2015. PubMed PMID: 26600425; PubMed Central PMCID: PMC4657971.

7: Sakaue Y, Domon H, Oda M, Takenaka S, Kubo M, Fukuyama Y, Okiji T, Terao Y. Anti-biofilm and bactericidal effects of magnolia bark-derived magnolol and honokiol on Streptococcus mutans. Microbiol Immunol. 2016 Jan;60(1):10-6. doi: 10.1111/1348-0421.12343. PubMed PMID: 26600203.

8: Yang C, Zhi X, Lv M, Xu H. Advances on Semisynthesis, Total Synthesis, and Structure-Activity Relationships of Honokiol and Magnolol derivatives. Mini Rev Med Chem. 2015 Nov 19. [Epub ahead of print] PubMed PMID: 26586125.

9: Yang B, Xu Y, Yu S, Huang Y, Lu L, Liang X. Anti-angiogenic and anti-inflammatory effect of Magnolol in the oxygen-induced retinopathy model. Inflamm Res. 2016 Jan;65(1):81-93. doi: 10.1007/s00011-015-0894-x. Epub 2015 Nov 7. PubMed PMID: 26547789.

10: Amorati R, Zotova J, Baschieri A, Valgimigli L. Antioxidant Activity of Magnolol and Honokiol: Kinetic and Mechanistic Investigations of Their Reaction with Peroxyl Radicals. J Org Chem. 2015 Nov 6;80(21):10651-9. doi: 10.1021/acs.joc.5b01772. Epub 2015 Oct 16. PubMed PMID: 26447942.

11: Lu SH, Hsu WL, Chen TH, Chou TC. Activation of Nrf2/HO-1signaling pathway involves the anti-inflammatory activity of magnolol in Porphyromonas gingivalis lipopolysaccharide-stimulated mouse RAW 264.7 macrophages. Int Immunopharmacol. 2015 Dec;29(2):770-8. doi: 10.1016/j.intimp.2015.08.042. Epub 2015 Sep 18. PubMed PMID: 26388191.

12: Kim SY, Kim J, Jeong SI, Jahng KY, Yu KY. Antimicrobial Effects and Resistant Regulation of Magnolol and Honokiol on Methicillin-Resistant Staphylococcus aureus. Biomed Res Int. 2015;2015:283630. doi: 10.1155/2015/283630. Epub 2015 Aug 19. PubMed PMID: 26357651; PubMed Central PMCID: PMC4556871.

13: Guo C, Ma L, Zhao Y, Peng A, Cheng B, Zhou Q, Zheng L, Huang K. Inhibitory effects of magnolol and honokiol on human calcitonin aggregation. Sci Rep. 2015 Sep 1;5:13556. doi: 10.1038/srep13556. PubMed PMID: 26324190; PubMed Central PMCID: PMC4555095.

14: Li M, Zhang F, Wang X, Wu X, Zhang B, Zhang N, Wu W, Wang Z, Weng H, Liu S, Gao G, Mu J, Shu Y, Bao R, Cao Y, Lu J, Gu J, Zhu J, Liu Y. Magnolol inhibits growth of gallbladder cancer cells through the p53 pathway. Cancer Sci. 2015 Oct;106(10):1341-50. doi: 10.1111/cas.12762. PubMed PMID: 26250568; PubMed Central PMCID: PMC4638010.

15: Liu Y, Wang D, Yang G, Shi Q, Feng F. Comparative pharmacokinetics and brain distribution of magnolol and honokiol after oral administration of Magnolia officinalis cortex extract and its compatibility with other herbal medicines in Zhi-Zi-Hou-Po Decoction to rats. Biomed Chromatogr. 2015 Jul 14. doi: 10.1002/bmc.3557. [Epub ahead of print] PubMed PMID: 26173910.

16: Xie NA, Hu C, Guo A, Liang H, DU P, Yin G. Metabolic regulation of magnolol on the nuclear receptor, liver X receptor. Exp Ther Med. 2015 May;9(5):1827-1830. Epub 2015 Feb 17. PubMed PMID: 26136900; PubMed Central PMCID: PMC4471739.

17: Kim SB, Kang HE, Cho HJ, Kim YS, Chung SJ, Yoon IS, Kim DD. Metabolic interactions of magnolol with cytochrome P450 enzymes: uncompetitive inhibition of CYP1A and competitive inhibition of CYP2C. Drug Dev Ind Pharm. 2016 Feb;42(2):263-9. doi: 10.3109/03639045.2015.1047846. Epub 2015 Jul 2. PubMed PMID: 26133083.

18: Lin MH, Chen MC, Chen TH, Chang HY, Chou TC. Magnolol ameliorates lipopolysaccharide-induced acute lung injury in rats through PPAR-γ-dependent inhibition of NF-kB activation. Int Immunopharmacol. 2015 Sep;28(1):270-8. doi: 10.1016/j.intimp.2015.05.051. Epub 2015 Jun 10. PubMed PMID: 26072062.

19: Liu T, Pan Y, Lai R. New mechanism of magnolol and honokiol from Magnolia officinalis against Staphylococcus aureus. Nat Prod Commun. 2014 Sep;9(9):1307-9. PubMed PMID: 25918799.

20: Liang X, Xing W, He J, Fu F, Zhang W, Su F, Liu F, Ji L, Gao F, Su H, Sun X, Zhang H. Magnolol administration in normotensive young spontaneously hypertensive rats postpones the development of hypertension: role of increased PPAR gamma, reduced TRB3 and resultant alleviative vascular insulin resistance. PLoS One. 2015 Mar 20;10(3):e0120366. doi: 10.1371/journal.pone.0120366. eCollection 2015. PubMed PMID: 25793876; PubMed Central PMCID: PMC4367990.